Alterity Therapeutics to Participate in Two Upcoming Investor Conferences
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Chairman’s Address 2021 Annual General Meeting
I am pleased to present my Chairman’s address at this year’s Annual General Meeting. For the second year in a row, we do this under uniq
Read More
Appendix 4C – Q1 FY22 Quarterly Cash Flow Report
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disord
Read MoreReceive news from Alterity Therapeutics
